US 9522910
Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
granted A61PA61P35/00
Quick answer
US patent 9522910 (Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon) held by OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA”
- Grant date
- Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 50
- CPC classes
- A61P, A61P35/00